Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Cancer Res. 2013 Apr 15;73(8):2435-44. doi: 10.1158/0008-5472.CAN-12-3381. Epub 2013 Feb 19.
The extent to which T-cell-mediated immune surveillance is impaired in human cancer remains a question of major importance, given its potential impact on the development of generalized treatments of advanced disease where the highest degree of heterogeneity exists. Here, we report the first global analysis of immune dysfunction in patients with advanced hepatocellular carcinoma (HCC). Using multi-parameter fluorescence-activated cell sorting analysis, we quantified the cumulative frequency of regulatory T cells (Treg), exhausted CD4(+) helper T cells, and myeloid-derived suppressor cells (MDSC) to gain concurrent views on the overall level of immune dysfunction in these inoperable patients. We documented augmented numbers of Tregs, MDSC, PD-1(+)-exhausted T cells, and increased levels of immunosuppressive cytokines in patients with HCC, compared with normal controls, revealing a network of potential mechanisms of immune dysregulation in patients with HCC. In dampening T-cell-mediated antitumor immunity, we hypothesized that these processes may facilitate HCC progression and thwart the efficacy of immunotherapeutic interventions. In testing this hypothesis, we showed that combined regimens to deplete Tregs, MDSC, and PD-1(+) T cells in patients with advanced HCC restored production of granzyme B by CD8(+) T cells, reaching levels observed in normal controls and also modestly increased the number of IFN-γ producing CD4(+) T cells. These clinical findings encourage efforts to restore T-cell function in patients with advanced stage disease by highlighting combined approaches to deplete endogenous suppressor cell populations that can also expand effector T-cell populations.
鉴于 T 细胞介导的免疫监视在人类癌症中的受损程度对广泛治疗高度异质性的晚期疾病的发展具有潜在影响,因此它仍是一个非常重要的问题。在这里,我们报告了对晚期肝细胞癌 (HCC) 患者免疫功能障碍的首次全球分析。我们使用多参数荧光激活细胞分选分析技术,对调节性 T 细胞 (Treg)、耗竭的 CD4(+)辅助 T 细胞和髓源性抑制细胞 (MDSC) 的累积频率进行定量,以同时了解这些不可手术患者的整体免疫功能障碍程度。与正常对照相比,我们记录到 HCC 患者的 Treg、MDSC、PD-1(+)耗竭 T 细胞数量增加,以及免疫抑制细胞因子水平升高,揭示了 HCC 患者免疫失调的潜在机制网络。在抑制 T 细胞介导的抗肿瘤免疫方面,我们假设这些过程可能促进 HCC 的进展,并破坏免疫治疗干预的疗效。在验证这一假设的过程中,我们表明,在晚期 HCC 患者中联合使用清除 Treg、MDSC 和 PD-1(+)T 细胞的方案可恢复 CD8(+)T 细胞产生颗粒酶 B,达到正常对照的水平,同时适度增加 IFN-γ 产生的 CD4(+)T 细胞数量。这些临床发现通过强调联合清除内源性抑制性细胞群的方法来恢复晚期疾病患者的 T 细胞功能,为患者提供了鼓励,这些方法还可以扩展效应 T 细胞群。